• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intensive hydroxyurea dosing in very young children with sickle cell anemia.

作者信息

Wang Winfred C, Brown R Clark, McNaull Melissa A, Rogers Zora R, Barton Martha, Dua Meghna R, Hankins Jane S, Gossett Jeffrey, Richardson Julie, Porter Jerlym S, Kang Guolian, Estepp Jeremie H

机构信息

Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN.

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.

出版信息

Blood Adv. 2023 Nov 28;7(22):6931-6935. doi: 10.1182/bloodadvances.2022009613.

DOI:10.1182/bloodadvances.2022009613
PMID:37695741
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10685164/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8361/10685164/7b51f80b8bf0/BLOODA_ADV-2022-009613-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8361/10685164/7b51f80b8bf0/BLOODA_ADV-2022-009613-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8361/10685164/7b51f80b8bf0/BLOODA_ADV-2022-009613-gr1.jpg

相似文献

1
Intensive hydroxyurea dosing in very young children with sickle cell anemia.对镰状细胞贫血幼儿进行强化羟基脲给药
Blood Adv. 2023 Nov 28;7(22):6931-6935. doi: 10.1182/bloodadvances.2022009613.
2
Hydroxyurea use among children with sickle cell anemia.羟基脲在镰状细胞贫血患儿中的应用。
Pediatr Blood Cancer. 2019 Jun;66(6):e27721. doi: 10.1002/pbc.27721. Epub 2019 Mar 22.
3
Hydroxyurea in very young children with sickle cell anemia is not a cure-all.羟基脲对镰状细胞贫血的幼儿并非万灵药。
J Pediatr. 2001 Dec;139(6):763-4. doi: 10.1067/mpd.2001.120093.
4
Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.羟基脲可预防镰状细胞贫血患儿蛋白尿的发生和进展。
Am J Hematol. 2019 Jan;94(1):E27-E29. doi: 10.1002/ajh.25329. Epub 2018 Nov 29.
5
[From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].[从血红蛋白SS到SF：羟基脲在两名刚果儿童镰状细胞病管理中的作用及文献综述]
Pan Afr Med J. 2015 Jun 15;21:124. doi: 10.11604/pamj.2015.21.124.5784. eCollection 2015.
6
Hydroxyurea for sickle-cell anaemia in Africa: mind the gap.非洲镰状细胞贫血的羟基脲治疗：注意差距。
Lancet Glob Health. 2015 Mar;3(3):e124-5. doi: 10.1016/S2214-109X(14)70371-7.
7
Hydroxyurea Improves Oxygen Saturation in Children With Sickle Cell Disease.羟基脲可提高镰状细胞病患儿的血氧饱和度。
J Pediatr Hematol Oncol. 2015 Apr;37(3):242-3. doi: 10.1097/MPH.0000000000000251.
8
Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.羟基脲在2至5岁镰状细胞病患儿中的应用。
J Pediatr Hematol Oncol. 2000 Jul-Aug;22(4):330-4. doi: 10.1097/00043426-200007000-00009.
9
Hydroxyurea therapy for sickle cell disease in Britain. Disappointing recruitment despite promising results.英国镰状细胞病的羟基脲疗法。尽管结果令人鼓舞，但招募情况令人失望。
BMJ. 1998 Jun 6;316(7146):1689. doi: 10.1136/bmj.316.7146.1689.
10
Hydroxyurea for ALL children with sickle cell anemia: What can we learn from Africa?羟基脲用于所有镰状细胞贫血儿童：我们能从非洲学到什么？
Pediatr Blood Cancer. 2020 Apr;67(4):e28164. doi: 10.1002/pbc.28164. Epub 2020 Jan 11.

引用本文的文献

1
The Current Role of Hydroxyurea in the Treatment of Sickle Cell Anemia.羟基脲在镰状细胞贫血治疗中的当前作用
J Clin Med. 2024 Oct 25;13(21):6404. doi: 10.3390/jcm13216404.
2
Factors associated with adverse outcome among children with sickle cell disease admitted to the pediatric intensive care unit: an observational cohort.入住儿科重症监护病房的镰状细胞病患儿不良结局的相关因素：一项观察性队列研究
Ann Intensive Care. 2024 Apr 10;14(1):55. doi: 10.1186/s13613-024-01283-5.

本文引用的文献

1
A meta-analysis of toxicities related to hydroxycarbamide dosing strategies.一项关于与羟基脲给药策略相关毒性的荟萃分析。
EJHaem. 2020 Apr 26;1(1):235-238. doi: 10.1002/jha2.7. eCollection 2020 Jul.
2
Fetal hemoglobin modulates neurocognitive performance in sickle cell anemia.胎儿血红蛋白可调节镰状细胞贫血患者的神经认知表现。
Curr Res Transl Med. 2022 Jul;70(3):103335. doi: 10.1016/j.retram.2022.103335. Epub 2022 Mar 15.
3
A call to start hydroxyurea by 6 months of age and before the advent of sickle cell disease complications.
呼吁在6个月大时且在镰状细胞病并发症出现之前开始使用羟基脲。
Pediatr Blood Cancer. 2022 Feb;69(2):e29423. doi: 10.1002/pbc.29423. Epub 2021 Nov 24.
4
Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia.通过精准研究优化羟基脲（HOPS）：镰状细胞贫血患儿随机多中心试验的研究方案
Trials. 2020 Nov 27;21(1):983. doi: 10.1186/s13063-020-04912-z.
5
Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.撒哈拉以南非洲地区镰状细胞贫血的羟脲剂量升级。
N Engl J Med. 2020 Jun 25;382(26):2524-2533. doi: 10.1056/NEJMoa2000146.
6
Sickle Cell Disease: Monitoring, Current Treatment, and Therapeutics Under Development.镰状细胞病：监测、当前治疗和正在开发的治疗方法。
Hematol Oncol Clin North Am. 2019 Jun;33(3):355-371. doi: 10.1016/j.hoc.2019.01.014. Epub 2019 Mar 28.
7
Hydroxyurea use in young infants with sickle cell disease.羟基脲在镰状细胞病婴幼儿中的应用。
Pediatr Blood Cancer. 2019 Jul;66(7):e27650. doi: 10.1002/pbc.27650. Epub 2019 Feb 7.
8
Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood.镰状细胞临床研究和干预计划 (SCCRIP)：一项从儿科阶段到成年期镰状细胞病进展的寿命队列研究。
Pediatr Blood Cancer. 2018 Sep;65(9):e27228. doi: 10.1002/pbc.27228. Epub 2018 May 24.
9
A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.羟基脲治疗期间镰状细胞贫血患儿具有临床意义的胎儿血红蛋白阈值。
Am J Hematol. 2017 Dec;92(12):1333-1339. doi: 10.1002/ajh.24906. Epub 2017 Sep 28.
10
Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia.羟基脲增加胎儿血红蛋白与镰状细胞贫血成人患者器官损伤减轻及生存期延长相关。
PLoS One. 2015 Nov 17;10(11):e0141706. doi: 10.1371/journal.pone.0141706. eCollection 2015.